Lenvatop

PRESENTATION:

Lenvatop 4 Capsule: Each capsule contains Lenvatinib Mesylate INN equivalent to Lenvatinib 4 mg.

Lenvatop 10 Capsule: Each capsule contains Lenvatinib Mesylate INN equivalent to Lenvatinib 10 mg.

Indication:

Lenvatop is a kinase inhibitor that is indicated-: • Hepatocellular Carcinoma (HCC): As a first-line treatment of patients with unresectable Hepatocellular Carcinoma (HCC). • Differentiated Thyroid Cancer (DTC): Single agent for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). • Advanced Renal Cell Carcinoma (RCC): In combination with Pembrolizumab, for the first line treatment of adult patients with advanced RCC In combination with Everolimus, for the treatment of patients with advanced RCC following one prior anti-angiogenic therapy. • Advanced Endometrial Carcinoma: In combination with Pembrolizumab, for the treatment of patients with advanced Endometrial Carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation

PACKAGING:

Lenvatop 4 Capsule: Each box contains 30 capsules and one packet silica gel in a sealed HDPE container.

Lenvatop 10 Capsule: Each box contains 30 capsules and one packet silica gel in a sealed HDPE container.